The Global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market is expected to grow from $202.12 million in 2016 to reach $1,350.23 million by 2023 with a CAGR of 31.2%

Friday, November 3, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 2, 2017 /PRNewswire/ -- According to Stratistics MRC, the Global NASH (Non-Alcoholic Steatohepatitis) Biomarkers

market is expected to grow from $202.12 million in 2016 to reach $1,350.23 million by 2023 with a CAGR of 31.2%. Rising demand for noninvasive diagnostic tools matched with growing levels of
patient awareness is likely to augment the growth of NASH biomarkers market over the forecast period. Furthermore, growing prevalence of chronic liver conditions is expected to upsurge demand for noninvasive diagnostic tools. On the contrary, huge price and invasiveness, ensued in changing the taste for noninvasive biomarkers is expected to limit the market growth over the forecast period.Read the full report: https://www.reportlinker.com/p05169991Biomarkers are commonly proteins detected in the blood, urine or other body fluids that are either raised by the tumor itself. Serum Biomarker should be measured at a low cost, by a widely usable assay with reproducible outcomes in a specimen that is comfortable to access. The serum biomarkers have the ability to deliver efficient results. Apoptosis markers follow this lead closely. Hospitals and diagnostic laboratories are likely to be rising in requirement for non-invasive NASH diagnostic and monitoring instruments at the ongoing tests by pharmaceutical manufacturers and CRO.North America holds the largest market share due to different reasons like rising prevalence of infectious diseases, cardiovascular diseases & cancer, rising R&D activities from key players, and favorable government initiatives. Asia Pacific is expected to become the fastest growing market owing to enlargement of key market participants. There is a substantial rise in R&D spending for biomarkers from the countries like China, India and Japan. In addition, increasing demand for biomarkers among end-users and rising number of CROs are factors favoring the market growth in this region.Some of the key players in global NASH (Non-Alcoholic Steatohepatitis) Biomarkers market include Allergan Plc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Dainippon Sumitomo Pharma (DSP), Enzo Biochem, GENFIT SA, Gilead Sciences, Inc. (GILD), Intercept Pharmaceuticals, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Prometheus Laboratories Corp, Raptor Pharmaceutical Corp and Siemens Heathcare Pvt. Ltd.Types Covered:• Hepatic fibrosis biomarkers• Serum biomarkers• Oxidative stress biomarkers• Apoptosis biomarkers• Other Biomarkers TypesApplication Types Covered:• Hospitals• Pharma & CRO Industry• Academic Research Institutes• Diagnostic LabsRegions Covered:North Americao USo Canadao MexicoEuropeo Germanyo UKo Italyo Franceo Spaino Rest of EuropeAsia Pacifico Japano Chinao Indiao Australiao New Zealando Rest of Asia PacificSouth Americao Argentinao Brazilo Chileo Rest of South AmericaMiddle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & AfricaWhat our report offers:- Market share assessments for the regional and country level segments- Market share analysis of the top industry players- Strategic recommendations for the new entrants- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)- Strategic recommendations in key business segments based on the market estimations- Competitive landscaping mapping the key common trends- Company profiling with detailed strategies, financials, and recent developments- Supply chain trends mapping the latest technological advancementsRead the full report: https://www.reportlinker.com/p05169991 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-nash-non-alcoholic-steatohepatitis-biomarkers-market-is-expected-to-grow-from-20212-million-in-2016-to-reach-135023-million-by-2023-with-a-cagr-of-312-300548931.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store